Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product

Haemanthus has reportedly raised as much as $20 million and received a Raman spectroscopy patent in January 2025, but has no publicly available commercial product or independently validated diagnostic results. The Austin startup says it plans to begin with veterinary testing; its former CTO said he resigned in March 2026, while an account attributed to CEO Billy Evans says he was let go. Holmes’ involvement remains disputed, and the article gives no launch timeline for the veterinary device.

Analysis

This is a diligence and financing signal, not a public-equity catalyst. The key asymmetry is that media attention may help Haemanthus attract private capital and veterinary pilot partners before it has demonstrated analytical validity; that can extend runway without reducing the core technical risk. A patent protects claims, not clinical performance, and the reported CTO departure increases execution and key-person risk while leaving the reason disputed.

The near-term downside is primarily private: weaker fundraising terms, delayed hiring, or a veterinary launch pushed out if independent test data are absent. Over 1–3 months, watch for reproducible sensitivity/specificity results, named validation partners, and a credible launch timeline. Over 6–18 months, successful veterinary validation could establish a lower-regulatory stepping stone, but human diagnostics would still face substantially higher validation and regulatory hurdles. Conventional diagnostics providers could face substitution only if performance, workflow, and cost are proven; there is no basis yet to price that threat into incumbents.

The contrarian angle is that attention is not purely negative: it can lower customer-acquisition and fundraising friction. But scrutiny also raises the cost of any claim that outruns evidence. The report of investment by early Palantir employees is not evidence of a Palantir Technologies investment or operating exposure; no PLTR read-through is warranted.

Key Decisions for Investors

• No trade in PLTR on this story. The reported connection concerns unnamed early employees, not a verified corporate investment; revisit only if Palantir Technologies confirms a material direct exposure.
• Treat Haemanthus as a private-market diligence watch, not a diagnostics disruptor thesis. Require independently replicated veterinary results, including sensitivity, specificity, sample size, and comparator methodology, before assigning value to the technology.
• Monitor for a veterinary product launch, validation-partner disclosure, or further senior technical departures over the next 1–3 months. A missed launch or continued absence of usable validation data would reinforce financing and execution risk; verified repeatable performance would weaken that view.
• Do not position against public diagnostic companies solely on the patent or documentary attention. Reassess substitution risk only after evidence that the device meets practical accuracy, throughput, and cost requirements in real-world use.